Josh Wolfe

Who they are

Josh Wolfe is Co-Founder and Managing Partner of Lux Capital — started the firm in 2000 out of Salomon Smith Barney, co-founded Variant Bio with scientists Kaja Wasik and Stephane Castel, and serves as Chairman of Coney Island Prep, the first charter school in Coney Island.

Person

Josh Wolfe co-founded Lux Capital in 2000 straight out of Wall Street — he'd done stints at Salomon Smith Barney, Merrill Lynch, and Prudential Securities across investment banking, municipal finance, and financial futures before deciding to build a fund around frontier science rather than trade around it. He graduated from Cornell in 1999 with a B.S. in Economics and Finance, and the move from sell-side analyst to deep-tech founder-VC is the sharpest signal about how he thinks: he's a builder who uses capital as a tool. Beyond Lux, he co-founded Variant Bio in 2018 alongside scientists Kaja Wasik and Stephane Castel, and served as Chairman of Kurion, a portfolio company. He's a longtime Board of Trustees member at the Santa Fe Institute (since 2015) and Chairman of Coney Island Prep, the first charter school in Coney Island — a consistent commitment to science education that runs parallel to the fund's identity. He writes for Forbes and edited the Forbes/Wolfe Emerging Tech Report; he posts actively on X (@wolfejosh) and has appeared on a wide circuit of podcasts — Knowledge Project, Odd Lots, The Portal with Eric Weinstein, Invest Like the Best, Prof G Pod — talking about defense tech, biotech, AI, and the philosophy of contrarian investing. The through-line is a bet that the most important companies emerge from scientific entropy — disorder others can't price — and that the investor's job is to sponsor that disorder before markets can.

Company

Lux Capital's most recent landmark is closing Fund IX in January 2026 at $1.5 billion — the firm's largest fund to date, oversubscribed — bringing total assets under management to $7 billion across 44 full-time professionals. That close came alongside two significant leadership additions: retired four-star General Tony Thomas and former U.S. diplomat Brett McGurk joined as venture partners, deepening Lux's credibility in defense and classified sectors. In 2025, the portfolio delivered two major exits — Chronosphere was acquired by Palo Alto Networks for $3.35 billion in November, and Matterport was acquired by CoStar Group for $2 billion in February. Also in 2025, Lux launched the Lux Helpline to support academic researchers facing federal funding cuts, and Lux Labs — formalized in 2024 as the firm's company-creation platform — launched a $100 million academic research partnerships initiative. Portfolio companies Databricks, Ramp, and Anduril are trading at secondary market premiums ahead of expected IPOs.

Market

Lux sits at the intersection of deep tech VC and defense-tech investing, where it considers itself a top-three specialist alongside In-Q-Tel, with Founders Fund and Khosla Ventures as the closest peer generalists in frontier science. The tailwinds are strong: venture investments in aerospace and defense reached $21.4 billion in 2025 across over 300 deals, and reduced public-sector R&D funding across federal agencies is creating private investment premiums in biotech and defense — exactly Lux's terrain. The firm is also leaning into a thesis that the next decade of value creation will be capital-intensive and physically constrained — permitting, infrastructure, material science — not just software, a deliberate counter-positioning against software-first VC.

Network

No direct relationship edges were surfaced in the data, but Wolfe's institutional affiliations place him in frequent contact with academic and policy networks: he's a Board of Trustees member at the Santa Fe Institute, has lectured at MIT, Harvard, Yale, Cornell, Columbia, and NYU, and has testified before the U.S. Congress on emerging technologies. Venture partners Tony Thomas (retired four-star General) and Brett McGurk (former U.S. diplomat) are the most recently added nodes in his professional orbit at Lux.

Tony Thomas· Venture Partner, Lux Capital (retired four-star General, former U.S. Army commander)
Brett McGurk· Venture Partner, Lux Capital (former U.S. diplomat)
Zach Iscol· Venture Partner, Lux Capital (emergency management background)
Kaja Wasik· Co-founder, Variant Bio
Stephane Castel· Co-founder, Variant Bio
Peter Hébert· Co-founder, Lux Capital

How they likely show up

Co-founded Lux in 2000 and has run it for 25+ years through multiple market cycles → thinks in decade-long arcs, not fund cycles; unlikely to be swayed by short-term market noise.
Active on X (@wolfejosh) and a Forbes columnist with named content themes (defense tech, AI, biotech, contrarian investing) → comfortable being publicly wrong-footed in service of a thesis; will engage directly with pushback.
Personally co-founded Variant Bio alongside scientists → doesn't just back founders, he builds alongside them; respects deep scientific credibility over pitch polish.
Santa Fe Institute trustee since 2015 and guest lecturer at six top universities → intellectual identity is central to how he shows up; complex systems thinking, not just financial engineering.
Testified before U.S. Congress on emerging technologies and recruited retired generals and diplomats as venture partners → operates at the policy-capital interface; geopolitical framing is not posture, it's part of the investment thesis.
Long-tenure pattern with consistent public voice on the same themes across 20+ years → high conviction, slow to pivot; values intellectual consistency over trend-chasing.

Conversation tips

→ Come in with a specific scientific or technical thesis — he responds to people who've gone deep on a domain, not broad tech optimists.
→ Reference a specific Lux quarterly report or podcast appearance (e.g. the 2025 Odd Lots episode on AI and Silicon Valley's social contract) — it signals you've done the actual reading.
→ Ask about the shift from software to physical assets — it's a live thesis he's articulating publicly, and he'll have strong, specific views on where most VCs are getting it wrong.
→ Don't try to flatter him on Lux's brand — he engages with substance; lead with a disagreement or a hard question and he'll respect it more than validation.
→ If you have a connection to the Santa Fe Institute, complexity science, or academic research funding cuts, surface it early — it's a genuine intellectual passion, not a side interest.

Toolbox

Openers

Open on Lux Labs — he launched it in 2024 as a formalized company-creation platform and followed it with a $100 million academic research partnerships initiative in 2025; it's his bet that the next generation of important companies starts in a lab, not a garage.
Reference the Lux Helpline launched in May 2025 — a direct response to federal R&D funding cuts, it's a telling move that shows how Lux positions itself as the private backstop for science when government pulls back.
Bring up the Fund IX close and the addition of a retired four-star General and a former U.S. diplomat as venture partners in January 2026 — it's a deliberate signal about where Lux thinks the next decade of value will be created: at the defense-science-policy intersection.

Discovery questions

Lux's thesis is that physical, capital-intensive businesses will dominate the next decade over pure software — where do you see most VCs still misallocating because they haven't updated that mental model?
You co-founded Variant Bio directly with scientists rather than just backing them — how does being a co-founder change what you're willing to demand from the companies you back?
With Tony Thomas and Brett McGurk now as venture partners, Lux has explicit military and diplomatic networks baked in — how does that change the kinds of deals or geographies you can access that you couldn't before?

Avoid

Don't pitch him on a software-first or pure-AI-productivity company without a hard science or physical-world substrate — his public thesis explicitly positions that category as the old paradigm, and he'll disengage quickly.

Make it yours